HealthDay News — For adults with severe alopecia areata (AA), ivarmacitinib, a selective Janus kinase 1 (JAK1) inhibitor, at doses of 4 and 8mg is efficacious and tolerable, according to a study ...

First Xolair biosimilar approved; wearable furosemide delivery system gains expanded indication; implant approved for macular telangiectasia; novel treatment shows promise in hypertension; and testing ...

The Food and Drug Administration (FDA) has approved Iluvien® (fluocinolone acetonide intravitreal implant) for the treatment of chronic non-infectious ...

Daridorexant, a dual orexin receptor antagonist, is currently approved for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.

Findings from MINT will be presented at the American Academy of Neurology Annual Meeting on April 8, 2025, in San Diego.

The recommendations were made following a meeting that included experts from the FDA, the Centers for Disease Control and Prevention, and the Department of Defense.

HealthDay News — Although most manufacturer reports of medical device adverse events are reported on time, a considerable proportion are submitted late, according to a study published online March 12 ...

HealthDay News — Short sleep (<7.7 hours) among adolescents is associated with elevated blood pressure (systolic ≥120mmHg and diastolic <80mmHg), according to a study presented at the American Heart ...

Hormone therapy has indirect effect on cognitive decline through regional tau accumulation; no links with tau for women younger than 70 years ...

Topline data were announced from a phase 2/3 trial evaluating Flebogamma 5% DIF (immune globulin intravenous ) in patients with post-polio syndrome (PPS).

GLP-1 RA use linked to lower risks for myelodysplastic syndromes, myeloproliferative neoplasms compared with metformin ...

CagriSema is a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a glucagon-like peptide-1 receptor agonist.